Dr. Mark H.N. Corrigan, MD
Dr. Corrigan is Chairman of the Board of Epirus Biopharmaceuticals, Inc. a public biopharmaceutical company, and from 2010 to 2014, he previously served as a director, president and chief executive officer of Zalicus Inc. prior to its merger with Epirus Biopharmaceuticals in July 2014. Prior to Zalicus, Dr. Corrigan joined the specialty pharmaceutical company Sepracor Inc. in 2003 (now known as Sunovion Pharmaceuticals, Inc.) where he served as Executive Vice President of Research and Development until December 2009. Prior to joining Sepracor, Dr. Corrigan spent 10 years with Pharmacia & Upjohn, where he served most recently as Group Vice President of Global Clinical Research and Experimental Medicine.
Before entering pharmaceutical industry, Dr. Corrigan spent five years in academic research at the University of North Carolina, School of Medicine, focusing on psychoneuroendocrinology; he maintains a faculty appointment as Adjunct Professor in the Psychiatry Dept. He is a Distinguished Fellow of the American Psychiatric Association. Dr. Corrigan has also chaired the Scientific Committee of the boards of directors of Avanir Pharmaceuticals and of Cubist Pharmaceuticals, Inc. Dr. Corrigan holds a B.A. and an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.